Palantir's Profit Sharing Agreement With Merck

Palantir's technology incorporated software to analyze the reams of pharmaceutical life sciences and clinic and chemical and clinical data. The deal marks the first step in a long partnership, giving Palantir a cut of Merck's resulting profits. They plan to eventually roll out the data tools to divisions of 349 year old German company. Later, they would form a joint research venture in late 2018 called Centropy. This allows users to structure and analyze data from desperate sources while also safeguarding data ownership.